Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1864663 (
HCC
)
2,985
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatitis B virus X protein plays a crucial role in the pathogenesis of hepatocellular carcinoma. We previously showed that the tumor suppressor
ARID2
inhibits hepatoma cell cycle progression and tumor growth. Here, we evaluated whether hepatitis B virus X protein was involved in the modulation of
ARID2
expression and hepatocarcinogenesis associated with hepatitis B virus infection.
ARID2
expression was downregulated in HBV-replicative hepatoma cells, HBV transgenic mice, and HBV-related clinical
HCC
tissues. The expression levels of HBx were negatively associated with those of
ARID2
in hepatocellular carcinoma tissues. Furthermore, HBx suppressed
ARID2
at transcriptional level. Mechanistically, the promoter region of
ARID2
gene inhibited by HBx was located at nt-1040/nt-601 and contained potential ATOH1 binding elements. In addition, ectopic expression of ATOH1 or mutation of ATOH1 binding sites within
ARID2
promoter partially abolished HBx-triggered
ARID2
transcriptional repression. Functionally,
ARID2
abrogated HBx-enhanced migration and proliferation of hepatoma cells, whereas depletion of ATOH1 enhanced tumorigenecity of
HCC
cells. Therefore, our findings suggested that deregulation of
ARID2
by HBx through ATOH1 may be involved in HBV-related hepatocellular carcinoma development.
...
PMID:HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma. 2849 50